News
1d
MyChesCo on MSNAclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis TreatmentWAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...
But if a particularly persistent and unsightly toenail fungus is giving you some trepidation, here is one powerful $19 ...
The AAP defines proactive care as an “ evidence-based ” approach based on “intermittent use of anti-inflammatory agents (eg, ...
Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results